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1. INTRODUCTION 
Herbal medicines are the oldest remedies known to mankind. Herbs had been 
used by all cultures throughout history. In the last few years, there has been an 
exponential growth in the field of herbal medicine and these drugs are gaining 
popularity both in developing and developed countries. India has a rich heritage of 
traditional knowledge and is a birth place to several important time-honoured 
systems of health care like Ayurveda, siddha and homeopathy. India is one of the 
largest producer of medicinal plants around the globe and is rightly called the 
"Botanical garden of the World"1. The herbal medicines serve the health needs of 
about 80% of the world’s population, especially for millions of people in the vast rural 
areas of developing countries; more than 65% of the global population uses 
medicinal plants as a primary health care modality.  
It is estimated that three quarter of the population rely on herbal and 
traditional medicine as a basic for primary health care2. Herbal formulations, which 
have attained widespread acceptability as therapeutic agent in India, includes  
neo-tropics, anti-diabetics, hepato-protective agents and lipid lowering agents there 
are many limitations regarding the safety and efficacy of these preparations. Herbal 
medicines are getting more popularity due to their potent antioxidant activity, 
minimal side effects and economic variability. 
 
HYPERLIPIDAEMIA 
Hyperlipidaemia is characterized by elevated serum total cholesterol, low 
density, and very low-density lipoprotein and decreased high-density lipoprotein 
levels3. It is also called hyperlipoproteinemia because these fatty substances travel 
in the blood attached to proteins. This is the only way that these fatty substances can 
remain dissolved while in circulation. Hyperlipidaemia associated lipid disorders are 
considered to cause atherosclerotic cardiovascular disease. Among these 
hypercholesterolemia and hypertriglyceridemia are closely related to ischemic heart 
disease. Hyperlipidaemia can be either primary or secondary type, the primary 
disease may be treated by antilipidemic drugs, but the secondary type originating 
from diabetes, renal lipid nephrosis or hypothyroidism demands the treatment of the 
original disease rather than hyperlipidaemia.4 
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Figure 1-Lipid profile normal values 
 
 
Hyperlipidaemia may basically be classified as either familial (also called 
primary hyperlipidaemia) caused by specific genetic abnormalities, or acquired (also 
called secondary) when resulting from another underlying disorder that leads to 
alterations in plasma lipid andlipoprotein metabolism (Chait et al 1990)5. Primary 
hyperlipidaemia may result from defects inthe hepatic uptake and degradation of 
LDL via the LDLR pathway, commonly caused by mutation in the LDLR gene or in 
the gene encoding apoB. The most recent gene in which defects cause 
hyperlipidaemia, is the gene encoding a member of the pro-protein convertase 
family, PCSK9. Mutations in PCSK9 associated with hypercholesterolemia. PCSK9 
normally down regulates the LDLR pathway by causing degradation of LDLR protein 
and mutation sin PCSK9 result in low plasma LDL levels (Soutar et al 2007)6. Also, 
hyperlipidaemia may be idiopathic without known cause. The most common causes 
are lifestyle habits or treatable medical conditions. Lifestyle habits include obesity, no 
physical activity, high dietary fat intakes, and smoking. Medical diseases that may 
lead to hyperlipidaemia are diabetes, kidney disease, pregnancy, and 
hypothyroidism (Ahmed et al 1998)7. One has a greater chance of developing 
hyperlipidaemia is old aged a man (45years) or a woman (55), heart diseases or 
familial history of hyperlipidaemia. Table 1 shows the common causes of secondary 
hyperlipidaemia. 
 
FAMILIAL (PRIMARY) 
Familial hyperlipidaemias are classified according to the Fredrickson 
classification, which is based on the pattern of lipoproteins on electrophoresis or 
ultracentrifugation. It was later adopted by the World Health Organization (WHO). It 
  INTRODUCTION 
 
DEPARTMENT OF PHARMACOLOGY, PADMAVATHI COLLEGE OF PHARMACY, DHARMAPURI Page 3 
 
does not directly account for HDL, and it does not distinguish among the different 
genes that may be partially responsible for some of these conditions. It remains a 
popular system of classification, but is considered dated by many. 8 
ACCORDING TO “FREDRICKSON” CLASSIFICATION, THERE ARE FIVE TYPES 
OF HYPERLIPIDAEMIA 
 Type I - Raised cholesterol with high triglyceride levels 
 Type II - High cholesterol with normal triglyceride levels 
 Type III - Raised cholesterol and triglycerides 
 Type IV - Raised triglycerides, atheroma, and raised uric acid 
 Type V - Raised triglycerides 
ACQUIRED (SECONDARY) 
Acquired hyperlipidaemias (also called secondary dyslipoproteinemias) may 
mimic primary forms ofhyperlipidaemia and can have similar consequences. They 
may result in increased risk of premature atherosclerosis or, when associated with 
marked hyper triglyceridemia, may lead to pancreatitis andother complications of the 
chylomicronemia syndrome. The most common causes of acquired hyperlipidaemia 
are: 
 Diabetes Mellitus 
 Use of drugs such as diuretics, beta blockers, and estrogens Other conditions 
leading to acquired hyperlipidaemia 
Include: 
 Hypothyroidism 
 Renal Failure 
 Nephrotic Syndrome 
 Alcohol 
 Some rare endocrine disorders and metabolic disorders 
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SIGNS AND SYMPTOMS OF HYPERLIPIDAEMIA 
Hyperlipidaemia usually has no noticeable symptoms and tends to be 
discovered during routine examination or evaluation for atherosclerotic 
cardiovascular disease.9,10 
1. Xanthoma 
2. Xanthelasma of eyelid 
3. Chest Pain 
4. Abdominal Pain 
5. Enlarged Spleen 
6. Liver Enlarged 
7. High cholesterol or triglyceride levels 
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8. Heart attacks 
9. Higher rate of obesity and glucose intolerance 
10. Pimple like lesions across body 
11. Atheromatous plaques in the arteries 
12. Arcussenilis 
13. Xanthomata 
CAUSES OF HYPERLIPIDAEMIA12 
1. Lifestyle habits or treatable medical conditions. Lifestyle contributors include 
Obesity, not exercising, and smoking 
2. Diabetes (type 2) 
3. Kidney disease 
4. Pregnancy 
5. An under active thyroid gland 
6. Environmental and genetic factors 
7. Alcohol 
8. Monoclonal Gammopathy 
9. Nephrotic Syndrome 
10. Obstructive Jaundice 
11. Hypothyroidism 
12.Cushing’s Syndrome 
13. Anorexia Nervosa 
14. Medications- 
 Thiazide Diuretics 
 Ciclosporin 
 Glucocorticoids 
 Beta Blockers 
 Retinoic Acid 
15. High dietary simple carbohydrates 
16. Estrogen therapy 
17. Lipoprotein lipase mutations. 
 
PATHOPHYSIOLOGY OF HYPERLIPIDAEMIA12 
Decreased clearance of triglycerides rich lipoproteins is due to inhibition of 
lipoprotein lipase and triglyceride lipase. Other factors such as peripheral insulin 
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resistance, carnitine deficiency, and hyperthyroidism may contribute to lipid 
abnormalities. In nephrotic syndrome, the decreased circulation of effective plasma 
albumin’s results in increased lipoprotein synthesis to maintain plasma oncotic 
pressure. 
 
PATHOPHYSIOLOGY OF HYPERCHOLESTEROLEMIA 
LDL cholesterol normally circulates in the body for 2.5 days, and subsequently 
binds to the LDL receptor on the liver cells, undergoes endocytosis, and is digested. 
LDL is removed, and synthesis of cholesterol by the liver is suppressed in the HMG-
CoA reductase pathway. In FH, LDL receptor function is reduced or absent, and LDL 
circulates for an average duration of 4.5 days, resulting in significantly increased 
level of LDL cholesterol in the blood with normal levels of other lipoproteins. In 
mutations of ApoB, reduced binding of LDL particles to the receptor causes the 
increased level of LDL cholesterol. It is not known how the mutation causes LDL 
receptor dysfunction in mutations of PCSK9 and ARH. 
Figure 2 – Biosynthesis of cholesterol 
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Although atherosclerosis occurs to a certain degree in all people, FH patients 
may develop accelerated atherosclerosis due to the excess level of LDL. The degree 
of atherosclerosis approximately depends of the number of LDL receptors still 
expressed and the functionality of these receptors. In many heterozygous forms of 
FH, the receptor function is only mildly impaired, and LDL levels will remain relatively 
low. In the more serious homozygous forms, the receptor is not expressed at all. 
Some studies of FH cohorts suggest that additional risk factors are generally at play 
when an FH patient develops atherosclerosis 13,14. In addition to the classic risk 
factors such as smoking, high blood pressure, and diabetes, genetic studies have 
shown that a common abnormality in the prothrombin gene (G20210A) increases the 
risk of cardiovascular events in patients with FH 15. Several studies found that a high 
level of lipoprotein(a) was an additional risk factor for ischemic heart disease16. The 
risk was also found to be higher in patients with a specific genotype of the 
angiotensin-converting enzyme (ACE). 
PATHOPHYSIOLOGY OF HYPERTRIGLYCERIDEMIA 
Hypertriglyceridemia may be the result of two processes. 
 One process is the overproduction of VLDL by the liver in response to an 
increase in free fatty   acids flowing to this organ.· 
 The other process is a defect in the lysis of VLDL triglycerides and 
chylomicrons by lipoprotein lipase. When lipoprotein lipase activity is deficient, 
triglycerides cannot be converted, hydrolyzed, or broken down, and the 
metabolism of chylomicron and VLDL remnants may be delayed, as in type III 
hyperlipoproteinemia (dysbetalipoproteinemia)17,18. 
 
POSSIBLE ATHEROGENIC CHANGES ACCOMPANYING 
HYPERTRIGLYCERIDEMIA 
 Plasma triglyceride levels less than 200 mg/dL are classified as normal. 
There has been some debate about whether an elevated triglyceride level is an 
independent risk factor for atherosclerosis. However, it is clearly associated with a 
number of metabolic or physiologic changes that are risk factors for this disease. 
These include: 
 Low HDL 
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 Unusually atherogenic forms of LDL Elevated triglycerides often reflect an 
increase in triglyceride-rich remnant lipoproteins that have atherogenic 
potential. 
 
DISEASES ASSOCIATED WITH HYPERLIPIDAEMIA  
Following are some diseases which are closely associated with 
hyperlipidaemia in various pathophysiology. 
 Atherosclerosis 
 Obesity 
 Diabetes mellitus 
 Renal disorders 
 Liver disorders 
 Thyroid diseases 
 Cushing`s syndrome 
 Hepatic lipase deficiency 
 Glycogen storage disease 
 
 
PREVELANCE 
Many studies have shown that there is a direct correlation between the incidence of 
coronary artery disease (CAD) and total low-density lipoprotein (LDL) cholesterol 
levels. Every year, approximately 1.5 million Americans experience an acute 
myocardial infarction and one-third of them do not survive. Because of adaption of 
the new NCEP GUIDELINES many more patients are now candidates for intensive 
lipid lowering therapy and these guidelines estimates  that the number of Americans 
who qualify for dietary treatment will rise from 52 million to 65 million, and the 
number who candidates for drug therapy will nearly triple-from 13 million to 36 
million. 
 
THE RISK FACTORS FOR HYPERLIPIDAEMIA ARE 
1. High fat intake is one of the factor which leads to hypercholesterolemia 
2. Type 2 diabetes mellitus 
3. Hypothyroidism 
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4. Chronic renal failure 
5. Nephritic syndrome 
6. Obesity 
7. Alcohol intake 
8. Drugs 
a. Number of drugs can adversely affect the serum lipid and lipoprotein 
concentrations. 
b. Antihypertensive agents 
c. Diuretics 
d. Oral contraceptives 
e. Corticosteroids- administration of glucocorticoids increases total cholesterol and 
TG by elevating LDL-C and to less extent VLDL-C 
9. Metabolic syndrome  
 
COMPLICATIONS OF HYPERLIPIDAEMIA 
 Pancreatitis 
 Premature coronary artery disease 
 Heart attack 
 Stroke 
 Atherosclerosis 
 Myocardial infarction 
PROGNOSIS 
Hyperlipidaemia is a condition characterized by an increased amount of fats 
(lipids) present in the bloodstream. The prognosis (outlook) for the condition varies 
according to a number of different factors. The prognosis for persons is in direct 
proportion to their serum cholesterol levels. Persons with hypercholesterolemia are 
at high risk of dying from heart disease or stroke. Many studies have looked at the 
relationship between elevated cholesterol levels, increased risk for heart attack and 
death. In one research investigation of relatively young males who had no known 
heart disease, cholesterol levels were measured and participants were followed for 6 
years. During this time, all heart attacks and deaths that occurred among participants 
were recorded. As serum cholesterol levels increased, so did the risk of experiencing 
a fatal heart attack. The risk of a fatal heart attack was approximately five times 
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higher among persons having cholesterol levels of 300 mg/dL or more compared to 
those with cholesterol levels below 200 mg/dL. The Framingham Heart Study is an 
ongoing research effort. Cholesterol levels, smoking habits, heart attack rates, and 
deaths in the population have been recorded for over 40 years. After 30 years, more 
than 85% of persons with cholesterol levels of 180 mg/dL or less were still alive; 
almost a third of those with cholesterol levels greater than 260 mg/dL had died [25-
26]. 
OUTLOOK (PROGNOSIS) 
Diet changes, exercise, and medications can lower cholesterol levels for 
those with the milder form of this disorder, and may significantly delay a heart attack. 
Men and women with familial percholesterolemia typically are at increased risk of 
early heart attacks. Risk of death varies among patients with familial 
hypercholesterolemia. Persons who inherit two copies of the defective gene have a 
poorer outcome. That type of familial hypercholesterolemia causes early heart 
attacks and is resistant to treatment. 
THE FACTS 
The American Heart Association reports that the lipids contained in the 
bloodstream include cholesterol, triglycerides, cholesterol compounds (esters) and 
phospholipids. Terms applied to various forms of hyperlipedemia include 
hypercholesterolemia, hypertriglyceridemia and hyperlipoproteinemia. 
TREATMENT FACTORS 
The Society for Vascular Surgery notes that treatments for hyperlipidaemia 
vary according to factors that include heart disease risk, lipid levels and a patient’s 
overall health. 
TREATMENT OPTIONS 
Potential treatments for lipid disorders include dietary changes,weight loss, 
regular exercise, quitting smoking, medications and periodic lipid screenings,  
reports the U.S. National Library of Medicine. 
UNSUCCESSFUL OUTCOMES 
The U.S. National Library of Medicine cites potential outcomes of 
unsuccessful high cholesterol treatment that include coronary artery disease, 
hardening of the arteries (atherosclerosis), heart attack, stroke and death. 
Unsuccessful treatment for high triglycerides can result in pancreatic inflammation 
(pancreatitis). 
  INTRODUCTION 
 
DEPARTMENT OF PHARMACOLOGY, PADMAVATHI COLLEGE OF PHARMACY, DHARMAPURI Page 11 
 
TREATMENT FOR HYPERLIPIDAEMIA 
HMG-COA REDUCTASE INHIBITORS (STATINS) 
Statins (or HMG-CoA reductase inhibitors) are a class of drugs used to lower 
cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a 
central role in the production of cholesterol in the liver. Increased cholesterol levels 
have been associated with cardiovascular diseases (CVD), and statins are therefore 
used in the prevention of these diseases. Statins have rare but severe adverse 
effects, particularly muscle damage, and some doctors believe they are 
overprescribed 19. 
Figure 3 –Treatment Guideline of Hyperlipidaemia 
 
 
The approved statins are 
o Atorvastatin 
o Fluvastatin 
o Lovastatin 
o Pravastatin 
o Rosuvastatin 
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o Simvastatin 
o Pitavastatin 
MODE OF ACTION 
Statins act by competitively inhibiting HMG-CoA reductase, the first committed 
enzyme of the HMGCoAreductase pathway. Because statins are similar to HMG-
CoA on a molecular level they take the place of HMG-CoA in the enzyme and reduce 
the rate by which it is able to produce mevalonate, the next molecule in the cascade 
that eventually produces cholesterol, as well as a number of other compounds. The 
HMG-CoA reductase pathway is blocked by statins via inhibiting the rate limiting 
enzyme HMG-CoA reductase. This ultimately reduces cholesterol via several 
mechanisms. Statins block the production of cholesterol in the liver itself. They lower 
LDL, the "bad" cholesterol, and triglycerides, and have a mild effect in raising HDL, 
the "good" cholesterol. These drugs are the first line of treatment for most people 
with high cholesterol. Side effects can include intestinal problems, liver damage, and 
in a few people,muscle tenderness 20. 
FIBRIC ACID DERIVATIVES (FIBRATES) 
Fibrates are cholesterol-lowering drugs that are primarily effective in lowering 
triglycerides and to a lesser extent in increasing HDL-cholesterol levels 21. 
Fibrates prescribed commonly are 
 Bezafibrate 
 Ciprofibrate 
 Clofibrate 
 Gemfibrozil 
 Fenofibrate 
MODE OF ACTION 
Fibrates are agonists of the PPAR-α receptor in muscle, liver, and other 
tissues. Activation of PPAR-α signaling results in: 
 Increased β-oxidation in the liver 
 Decreased hepatic triglyceride secretion 
 Increased lipoprotein lipase activity, and thus increased VLDL clearance 
 Increased HDL 
 Increased clearance of remnant particles 
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Fibrates activate PPAR (peroxisome proliferatoractivated receptors), 
especially PPARα. The PPARs are a class of intracellular receptors that modulate 
carbohydrate and fat metabolism and adipose tissue differentiation. Activating 
PPARs induces the transcription of a number of genes that facilitate lipid 
metabolism. Fibrates are structurally and pharmacologically related to the 
thiazolidinediones, a novel class of anti-diabetic drugs that also act on PPARs (more 
specifically PPARγ) 
BILE ACID SEQUESTRANTS 
The bile acid sequestrants are a group of medications used to bind certain 
components of bile in the gastrointestinal tract. They disrupt the enterohepatic 
circulation of bile acids by sequestering them and preventing their reabsorption from 
the gut. In general, they are classified as hypolipidemic agents, although they may 
be used for purposes other than lowering cholesterol. They are used in the treatment 
of chronic diarrhea due to bile acid malabsorption. When the statins are not sufficient 
to lower high cholesterol, these drugs can be added. Their use is often limited by 
side effects, which are primarily gastrointestinal. They can include nausea, bloating, 
cramping, and an increase in liver enzymes.  Three drugs are members of this class; 
all are synthetic polymeric resins: 
 Cholestyramine 
 Colesevelam 
 Colestipol 
MODE OF ACTION 
Bile acid sequestrants are polymeric compounds that serve as ion exchange 
resins. Bile acid sequestrants exchange anions such as chloride ions for bile acids. 
By doing so, they bind bile acids and sequester them from enterohepatic circulation. 
Since bile acid sequesterants are large polymeric structures, they are not well 
absorbed from the gut into the bloodstream. Thus, bile acid sequestrants, along with 
any bile acids bound to the drug, are excreted via the feces after passage through 
the gastrointestinal tract 22. 
NICOTINIC ACID FOR HIGH CHOLESTEROL 
MODE OF ACTION 
Nicotinic acid reduces the production of triglycerides and VLDL (very low-
density lipoprotein, which is converted to LDL in the blood). This leads to decreased 
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LDL ("bad") cholesterol, increased HDL ("good") cholesterol, and lowered 
triglycerides Nicotinic acid raises HDL cholesterol more than other lipid-lowering 
medicines. The nicotinic acid form of niacin lowers cholesterol, but other forms of 
niacin do not. The other forms that do not lower cholesterol include nicotinamide and 
inositol nicotinate (also called no-flush niacin) 23. 
 
FREE RADICALS 
The Free radicals24 are chemical species which have an unpaired electron 
(represented as R·). Free radicals are some of the potent chemically active 
compound that need to pair its single electron, thus it must abstract a second 
electron from a nearly attaching molecule. This results in the production of yet other 
free radical and self-reacting steps of reaction sequences. This reactions including 
free radicals are usually divided by three distinct steps such as initiation 
phase, propagation phase and termination phase25. 
 Initiation reactions are those started for the number of free radicals 
multiplication. The free radicle generated by stable species reactions. 
 Propagation reactions are those in which the total number of free radicals 
remains the same but formation and destruction of free radicle are balanced. 
 Termination reactions are those reactions resulting total decrease amount of 
free radicals. However, combination of two or three free radicals  to convert 
stable species, for example: 2Br .→ Br2 
Free radical generation in  human body can start from modern life style 
habituates such as high fatty meal, alcohol consumption, smoking, environmental 
pollutants, ozone,  ionisation, toxins, carcinogen toxins etc. The vast majority of free 
radicals originates within the body, an unavoidable enzymatic chemical reaction 
leading to free radical by product of living system. Under possible condition reactive 
free radical intermediates are synthesised in living tissues, the biochemical reaction 
in the body neutralise this free radical formation by the breakdown of compounds via 
biotransformation via metabolic enzymes. The primary sources of free radicals (such 
as O2
- and HO2·) are produced due to the leakages from the electron transport 
chains in mitochondria, endoplasmic reticulum and chloroplasts. 
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DANGEORUS ACTION OF THE FREE RADICALS: 
These are four species of free radicals destruction 26: 
1. Lysosomes damages: Lysosomes are the self-digesting enzyme which 
present in little space inside cell that stored degenerative enzymes. These 
enzymes release when the cell wall breakage, digesting their own cell portions 
and little bit spreads to nearby cell acting a step by step reaction followed 
destruction of cells. 
2. Oxidation of the fat compounds: The fatty membranes covered on the cells 
being the prime target of free radicals attacks, these damaged membranes 
then lose its ability to transport oxygen, water or nutrients to the cells. 
3. Denaturation of the protein molecules: Free radicals are attack inside 
nucleic acid are comprises the genetic code in every cell. The function of 
nucleic acids is to control physiological cell function, growth and modulation of 
the damaged tissues. 
4. Cell necrosis: Damages done to the chromosomes and nucleic acids may 
induce the growth of unchaped cells in the body, which was the first step in 
cancer development. 
EFFECTS OF FREE RADICAL OXIDATION STRESS: 
Formation of reactive oxygen species and other synthesised free radicals65 
cause damages to various chemicals and cells also result affect in the toxicity of 
chemicals, cause ageing of the cells and different age-related disorder, including: 
 Cardiovascular: Heart Attack, High Blood Pressure, Angina, Stroke, and                      
Atherosclerosis. 
 Lungs  : Asthma, Allergies, COPD, Cancer, Chronic Bronchitis 
 Brain  : Alzheimer’s, Parkinson's, Migraine, Insomnia, Lack of Mental  
Clarity, Depression, Bipolar, Dementia 
 Joints  : Osteoarthritis and Rheumatoid arthritis  
 Eyes   : Cataracts, Macular & Retinal Degeneration 
 Skin  : Wrinkles, Acne, Skin Aging, Eczema, Cancer, Psoriasis  
 Immune  : Cold and Flu, Autoimmune, HIV, Herpes, Cancer, Ulcerative  
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Colitis, Chronic Viral Disease, Crohn's, Lupus, Hepatitis 
 Multi organ    : Diabetes, Chronic Fatigue, Fibromyalgia, Heavy metal  
Toxicity, Aging. 
SOURCES OF FREE RADICALS: 
Free radicals are produced during the various metabolic activities carried out 
inside our body and also get exposed to free radicals present in the environment. For 
example: 
Exogenous sources:Sunlight, Automobile Exhaust, Cigarette Smoke, Alcohol 
Consumption, Emotional Stress, Pollutants, UV light, Xenobiotics, Ionising radiation 
and Exposure to Heavy metals like Mercury, Lead, Cadmium etc 
Endogenous sources: Mitochondrial leak, Respiratory burstand Enzyme reactions 
 
 
TYPES OF FREE RADICALS IN THE BODY: 
One of the important species of  free radicals inside the body is the radical 
derivatives of oxygen commonly called as reactive oxygen species27 .These include 
  INTRODUCTION 
 
DEPARTMENT OF PHARMACOLOGY, PADMAVATHI COLLEGE OF PHARMACY, DHARMAPURI Page 17 
 
oxygen in its triplet state or singlet state, superoxide anion, hydroxyl radical , nitric 
oxide, peroxynitrite, hypochlorous acid, hydrogen peroxide, alkoxyl radical, and the 
peroxyl radical. Others are carbon-centered free radical that produced in oxidizing 
radical of organic compound. Hydrogen-centered radicals produced from reaction 
the H atoms.                  
Table 1- Type of Reactive Oxygen Species 
 
ANTIOXIDANTS 
The human body also has several natural chemical species or systems for 
neutralizing free radicals via normal chemical reaction. These agents that neutralize 
and inhibit the free radical damage, to give or gain an unpaired electrons to get free 
radicals have attach without produce any harmful effect. Antioxidants are chemical 
molecule it may be protect about cell necrosis against the action of free radicals. 
These are the substances produced when body damaged through food consumption 
or by the environmental exposures of radiation or tobacco smoke by active and 
passive smokers28. This substances are nutrients (vitamins and minerals) and 
enzymes (proteins is affect the metabolism in the body). This compound believed to 
play a vital role for the prevention of the treatment of chronic malignancy, congestive 
disease, stroke, neurodegenerative disorder (Alzheimer's disease, Parkinsonism) 
and cataracts. Antioxidant substances include Beta-carotene, Lycopene, Lutein, 
Selenium and Vitamins A,C,E. 
Reactive Oxygen Species 
O2?⁻ Superoxide radical 
?OH Hydroxyl radical 
ROO? Peroxyl radical 
H2O2 Hydrogen peroxide 
1O2 Singlet oxygen 
NO? Nitric oxide 
ONOO⁻ Peroxynitrite 
HOCl Hypochlorous acid 
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Antioxidants get their name because they prevent oxidation. Oxidation is a 
reaction in which a molecule loses its electron. The two important formation route of 
antioxidants are: 
 Those get food or food derivatives 
 Those synthesised our own body parts. 
TYPES OF ANTIOXIDANTS 
 Antioxidant Nutrients29 
Antioxidantsconsume by our diet appear to have an importance in trapping 
free radical generation. Each nutrient have unique by structure and chemical 
reaction methods.  
Vitamin E is a generic word that indicated to all compounds (eight found up 
to now) have biological action as of the isomer tocopherol. The Alpha-isomer have 
the heights potency, with action inside tissues. It is a fat-soluble compound safe 
guard at cell membrane from the free radicle damage. It is also supress the fat cell 
containing low-density lipoproteins (LDLs or bad cholesterol) from oxidation 
process.  
Vitamin C, also called as ascorbic acid, it is soluble in aqueous vehicle. It 
neutralise the free radicals in body fluids, such as inside from the cells. Vitamin C 
react addictive action with vitamin E to reduce the free radicals and regenerates its 
reduced (stable) form of tocopherol.  
Beta-carotene, also a water-soluble vitamin supplement it is the most widely 
evaluated carotenoids identified still now. It is act as a best quenching agent 
compared to the singlet oxygen species. Beta-carotene have an excellent in 
scavenging free radicals at low oxygen concentration.  
Selenium is a little tracing compound element but it not survive and form 
coenzyme at several antioxidant enzymes (example-glutathione peroxidase).  
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Like this several enzymes and minerals zinc and manganese are trace 
elements that form an important part of various type antioxidant enzymes30.   
 Antioxidant Enzymes 
The antioxidant enzymes such as superoxide dismutase (SOD), catalase 
(CAT) and glutathione peroxidase (GPx) act as primary line of the defence 
in destruction free radicals inside the body.  
SOD initially reduced (adds an electron to) as radical superoxide (O2-) 
subsequently convert a molecule of hydrogen peroxide (H2O2) and molecule of 
oxygen (O2).  
  2O2- + 2H ----SOD-->  H2O2 + O2 
Catalase &GPx simultaneously work with glutathione is a protein to reduce to 
convert hydrogen peroxide and subsequent product is the water (H2O).  
  2H2O2    ---CAT--->  H2O + O2 
  H2O2 + 2 molecule of glutathione            oxidized form glutathione + 
2H2O 
 Other type of Antioxidants 
In addition to enzymes, minerals and vitamins, there are many other nutrients 
and compounds that have antioxidant properties. Among them is coenzyme Q10 
(CoQ10, or ubiquinone), which is essential to energy production and can also protect 
the body from destructive free radicals. Also product of DNA metabolism, uric acid, 
has become increasingly recognized as an important antioxidant. Additionally, 
phytochemicals are being investigated for their antioxidant activity and health-
promoting potential.  
ANTIOXIDANT PROCESS 
Antioxidants block the process of oxidation by neutralizing free ions and they 
become oxidized. Thus there is a balance need to replenish among the antioxidant 
resources. Their work is classified by one of two methods31:  
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 Chain-breaking - When a free radical issues or traps an electron, a secondary 
radical is generated. These compounds then changed around and repeat the 
same process to the next molecule, generating more unstable products. This 
reaction continues up to a termination occurs, so the radical is neutralised  
 Preventive - Antioxidant enzymes like catalase, superoxide-dismutase and 
glutathione peroxidase supress oxidation reaction by a decreasing the kinetic of 
chain initiation through scavenging initiating radical, these antioxidants can 
stabilise oxidation chain from ever setting in motion. It also separate oxidation 
by stabilizing transition metal radical copper and iron.  
The effectiveness of any given antioxidant in the body depends on type of free 
radical involved, its generation and the target of damage. In certain conditions, an 
antioxidant may even acted by pro-oxidant that generates toxic oxygen species.  
A good number of medicinal plants are found mentioned in the ancient classical 
Ayurvedic texts 'CharakaSamhita'. 'SusrutaSamhita' and 'AstangaHrdayaSamhita'. 
But many of them still remain to be properly identified32. During the process of 
urbanization the contact with plants in their natural habitat was lost, creating 
confusion in the correct identity of many plants.  
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2. LITERATURE REVIEW 
1. S. Chackrewarthy, M. I. Thabrew, M. K. B. Weerasuriya, and S. Jayasekera. 
Evaluation of the hypoglycemic and hypolipidemic effects of an ethylacetate fraction 
of Artocarpusheterophyllus (jak) leaves in streptozotocin-induced diabetic rats. 
Pharmacogn Mag, 2010 Jul-Sep; 6(23): 186–190. 
S.Chackrewarthy et al34 in his study investigates the hypoglycemic and 
hypolipidemic effects of an ethylacetate (EA) fraction of the mature leaves of A. 
heterophyllus in a streptozotocin (STZ) induced diabetic rat model. In normoglycemic 
rats, administration of a single dose (20 mg/kg) of the EA fraction resulted in a 
significant (P < 0.05) reduction in the fasting blood glucose concentration and a 
significant improvement in glucose tolerance (P < 0.05), compared to the controls. In 
STZ-induced diabetic rats, chronic administration of the EA fraction of A. 
heterophyllus leaves daily for 5 weeks resulted in a significant lowering of serum 
glucose, cholesterol and triglyceride (TG) levels. Compared to control diabetic rats, 
the extract-treated rats had 39% less serum glucose, 23% lower serum total 
cholesterol and 40% lower serum TG levels and 11% higher body weight at the end 
of the fifth week. 
2. E.R.Suchithra and S. Subramanian. Antidiabetic activity of 
Artocarpusheterophyllus rag extract studied in high fat fed- low dose STZ induced 
experimental type 2 diabetic rats. Der Pharmacia Lettre, 2014, 6 (3):102-109 
Haidy S. Omar et al34 examined the antioxidative, hypoglycemic, and hypolipidemic 
activities of Artocarpusheterophyllus (jack fruit) leaf extracts. Various extracts like 
70% ethanol n-butanol, water, chloroform, and ethyl acetate extracts are examined. 
The administration of 70% ethanol extract or n-butanol extract to streptozotocin 
(STZ)-diabetic rats significantly reduced fasting blood glucose (FBG) from 200 to 56 
and 79 mg%, respectively; elevated insulin from 10.8 to 19.5 and 15.1 µU/ml, 
respectively; decreased lipid peroxides from 7.3 to 5.4 and 5.9 nmol/ml, respectively; 
decreased %glycosylated hemoglobin A1C (%HbA1C) from 6.8 to 4.5 and 5.0%, 
respectively; and increased total protein content from 2.5 to 6.3 and 5.7 mg%, 
respectively. Triglycerides (TG), total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C), VLDL-C, and LDL/HDL ratio significantly declined by -37, -19, -
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23, -37, and -39%, respectively, in the case of 70% ethanol extract; and by -31, -14, -
17, -31, and -25%, respectively, in the case of n-butanol extract; as compared to 
diabetic rats. HDL-C increased by +37% (70% ethanol extract) and by +11% (n-
butanol extract). Both JFEE and JFBE have shown appreciable results in decreasing 
FBG, lipid peroxides, %HbA1C, TC, LDL-C, and TG levels, and increasing insulin, 
HDL-C, and protein content. 
3.P. Sivagnanasundaram and K. O. L. C. Karunanayake. Phytochemical Screening 
and Antimicrobial Activity of Artocarpusheterophyllus and Artocarpusaltilis Leaf and 
Stem Bark Extracts. OUSL Journal, 2015; 9, 1-17. 
Venkateswaruluet al35 in his study used aqueous extract from 
Artocarpusheterophyllus leaves to evaluated for its hypocholesterolaemic and 
hypotriglyceridemic activities. The animals were divided into Normal (CG), Triton 
treated group (T), Triton plus Atorvastatin, Triton plus herb extract 200 mg/kg, Triton 
plus herb extract 400 mg/kg, treated groups. Oral administration of 
Artocarpusheterophyllus leaf extract (200 mg/kg and 400 mg/kg) in both groups At 
24 hrs after treatment with TRITON WR 1339 caused a significant decrease in 
serum lipid parameters like Triglycerides (TG), Cholesterol (CH), LDL- cholesterol, 
Atherogenic index (AI), LDL/HDL Ratio and Total proteins as like in atorvastatin 
treated groups. The both extract treated groups and atorvastatin treated group 
bought about a significant increase in HDL-Cholesterol levels.                                                                                                                                
4.Periyanayagam K*, Karthikeyan V. Wound Healing Activity Of The Leaves Of 
ArtocarpusHeterophyllus Lam. (Moraceae) On Ex-Vivo Porcine Skin Wound Healing 
Model. Innovare Journal of Life Science  2013; 1 (1) 28-33. 
K Periyanayagam et al36 studied thewound healing activity of the leaves of 
artocarpusheterophyllus lam. (moraceae) on ex-vivo porcine skin wound healing 
model and found that  that the ethyl acetate extract of the leaves possesses potential 
wound healing activity. 
5. Venkateswarulu .M, Prashanthi.K,GopichandChinta, Sujata .D, Pushpakumari.B, 
Ranganayakulu.D. Anti-hyperlipidemic activity of the aqueous extract of the 
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Artocarpusheterophyllus leaves in triton WR-1339 induced hyperlipidemic rats.Drug 
Invention Today. 2010;2(1),25-28. 
P. Sivagnanasundaram et al37 evaluated the antimicrobial and phytochemical 
properties of Artocarpusheterophyllus in leaf and stem bark extracts Hexane, 
dichloromethane and ethanol were used as extraction solvents and test organisms 
were Escherichia coli, Micrococcus luteus, Aspergillusniger and Trichoderma sp. A 
disc diffusion test was adopted to test the susceptibility of the selected microbes to 
the extracts while Minimum inhibitory concentration (MIC) was determined using 
serial dilution of extracts. Ethanolic stem bark extracts (30mg/ml) of 
A.heterophyllusexibits significant antibacterial activity against Escherichia coli with 
9.50 ± 0.44 inhibition zone radii. Dichloromethane extracts of leaf and stem bark 
showed lesser antibacterial activity against both of the bacteria with inhibition zones 
of 3.00 ± 0.34 mm to 5.66 ± 0.16 mm while hexane extracts did not show any 
antibacterial activity. Antifungal activity on the other hand was not detected in any of 
the extracts. Phytochemical screening confirmed the presence of phytosterols, 
anthraquinone, terpenoids, phenols, glycosides, flavonoids and diterpenes. 
6. Omar HS, El-Beshbishy HA, Moussa Z, Taha KF, Singab AN. Antioxidant activity 
of Artocarpusheterophyllus Lam. (Jack Fruit) leaf extracts: remarkable attenuations 
of hyperglycemia and hyperlipidemia in streptozotocin-diabetic rats.Scientific World 
Journal. 2011; 5(11):788-800. 
E. R. Suchithra et al38  studied the antidiabetic activity of Artocarpusheterophyllus 
rag extract studied in high fat fed- low dose STZ induced experimental type 2 
diabetic rats” reports that Artocarpusheterophyllus rag possess antibacterial, anti-
inflammatory, antioxidant and immune modulatory properties. In the study Diabetic 
rats were treated with Artocarpusheterophyllus rag extract at a dosage of 300 mg/kg 
b.w daily for 30 days. Metformin (200 mg/kg. b.w) was used as a reference drug and 
fasting blood glucose, plasma insulin and HbA1c were theparameters under 
consideration. The extract supplementation attenuated the elevated levels of 
glucose, glycosylated hemoglobin, AST, ALT and ALP. The insulin level was 
improved with an improvement in hepatic glycogen content of insulin resistant 
diabetic rats. The altered activities of glycogen metabolizing enzymes were 
normalized upon extract treatment. Also the extract improves insulin sensitivity which 
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is evident from intraperitoneal insulin tolerance test. The results show that the rags of 
Artocarpusheterophyllus are non-toxic and possess significant antidiabetic 
properties. 
7. Sanwar Mal Lamba,Kunjbihari Sulakhiya,Parveen Kumar. Anti 
diabetic,Hypolipidemic and Anti oxidant activities of Hydroethanolic Root Extract of 
Rhus Mysurensis Heyne in streptozotocin induced Diabetes in Wistar Male Rats. 
Sanwar Mal Lamba et al60   Studied Anti diabetic, Hypolipidemic and Anti oxidant 
Activities  of hyroethanolic root extracts of Rhus mysurensis (HERM) in the treatment 
of diabetes along with its antioxidant and hypolipidemic effects were studied in 
streptozotocin induced diabetes in wistar rats. In this study, the 
antidiabetic,hypolipidemic and anti oxidant activities of hydroethanolic root extract of 
Rhus mysurensis was evaluated by using STZ induced diabetic rats at a dose of 
200mg/kg,400mg/kg and 800mg/kg p.o. daily for 21 days. Blood glucose levels and 
body weight were monitored at specific time intervals, and different biochemical 
parameters, serum cholesterol, serum triglyceride, high density lipoprotein, low 
density lipoprotein were also assessed in the experimental animals.  
8. Damayanthi Dalu, Satyavati Dhulipala. Antidiabetic,Antihyperlipidemic and 
Antioxidant Properties of Root of Ventilago Maderaspatana Gaertn. On 
Streptozotocin Induced Diabetic Rats. 
Damayanthi Dalu et al61 Studied Antidiabetic,Antihyperlipidemic and Antioxidant 
Activities of alcoholic root extracts of Ventilago maderaspatana were evaluated for 
toxicity unto 3000mg kg. In oral glucose tolerance test chloroform extract did not 
produce significant glucose lowering effect. Alcoholic extract of V.maderaspatana 
(VMAE and VMHAE) elicited significant glucose tolerance effect. Hence VMAE and 
VMHAE were screened further by streptozocin induced diabetic model.VMAE and 
VMHAE significantly lowered blood glucose, triglycerides, total cholesterol, LDL 
cholesterol, VLDL cholesterol, creatinine, urea and increased HDL cholesterol,serum 
insulin and liver glycogen levels when compared to standard drug 
glibenclamide(10mg kg).V.maderaspatana also increased catalase levels and 
decreased lipid peroxidise and glutathione reductase.VMAE and VMHAE elicited 
significant dose dependent antidiabetic,antihyperlipidemic and antioxidant 
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activity.VMHAE at 500 mg kg induced more significant antidiabetic activity than 
VMAE (500 mg kg) elicited more antihyperlipidemic and antioxidant activity copared 
to VMHAE(500 mg kg). 
9. Prashant R. Verma, Prakash R. Itankar, Sumit K. Arora. Evaluation of antidiabetic 
antihyperlipidemic and pancreatic regeneration, potential of aerial parts of Clitoria 
ternatea. 
P.R.Verma et al62, studied  Antidiabetic, Antihyperlipidemic and Pancreatic 
regeneration of ethanol extract of Clitoria ternatea L. Fabaceae. The antidiabetic and 
antihyperlipidemic potential was evaluated in streptozotocin induced diabetic rats 
and correlated with its in vitro antioxidant activity. The extract and its fractions were 
initially screened for acute and sub chronic antidiabetic activity in the dose range of 
100-200 mg/kg. The most potent extract and fractions were further evaluated for 
pancreatic beta cells regeneration activity along with antioxidant and 
antihyperlipidemic activity. The polyphenolic activity. The most significant pancreatic 
regeneration activity,antidiabetic and antihyperlipidemic activity and was shown by 
ethanol extract and butanol soluble fraction at a dose level of 200 mg/kg, while rutin 
was found to be least potent. In conclusion, pancreatic regeneration studies of 
ethanol extract treated rats show nesidioblastosis. It is also suggested that the 
factors causing regeneration are present within the pancreas. The newly generated 
islets may have formed from the ductal precursor cells and reduced oxidative stress 
helps in restoration of beta cell function. 
10. Pradeep Pal,Ajay Sharma,Mukesh Mehra,Anil Choudhary.  Antidiabetic and 
Antihyperlipidemic activity of ethanolic extract of Artemisia Nilagirica In 
streptozotocin induced diabetic rats. 
Pradeep Pal et al63, as studied Antidiabetic and Antihyperlipidemic activity of 
ethanolic extract of Artemisia Nilagirica . Diabetes mellitus is characterized by 
elevated plasma glucose concentration resulting from insufficient insulin and insulin 
resistance, or both, leading to metabolic abnormalities in carbohydrates, lipid and 
protein.  The antidiabetic effects of ethanolic extract of leaf were monitored at 
specific intervals. 
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3. PLANT PROFILE 
 
 
Figure 4: Photograph of Artocarpus heterophyllus39 
TAXONOMICAL CLASSIFICATION        
Table: 2 – Taxonomical classification of Artocarpus heterophyllus40 
Kigdom Plantae 
Division Magnoliophyta 
Class Magnoliopsida 
Order Rosales 
Family Moraceae 
Genus Artocarpus 
Species A. heterophyllus 
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VERNACULAR NAMES 
Table: 3 – Vernacular names of Artocarpus heterophyllus41 
 
 
 
 
 
 
 
 
 
Global Distribution: Western Ghats of India, Malaysia and also found in central and 
eastern Africa, south-eastern Asia, the Caribbean, Florida, Brazil, Australia, Puerto 
Rico and many Pacific Islands  
PLANT DESCRIPTION42: 
It is a large, evergreen tree, 10-15m in height, indigenous to the evergreen 
forests at altitude of 450-1,200m and cultivated throughout the hotter parts of India. 
Stem of this plant is straight rough whereas bark is green or black, 1.25cm thick, 
exuding milky latex, leaves broad obovate, elliptic, decurrent, glabrous, entire 
inflorescence solitary axillaries, cauliforous and ramflours on short leafy shoots. Male 
head is sessile or on short peduncles receptacles, sometimes born on the ultimate 
twing, Female head are oblong ovoid receptacle, syncarpus, cylindrics. Seeds are 
separated horny endocarpus enclosed by sub-gelatinous exocarpus (1mm thick) 
oblong ellipsoid in nature. The sweet yellow sheaths around the seeds are about 3-5 
mm thick and have a taste similar to that of pineapple, but milder and less juicy. 
 
 
LANGUAGES NAMES 
English Jackfruit 
Bengali Kanthal 
Hindi Kathal, Panas 
Malayalam Chakka 
Marathi Phanas 
Tamil Palaa 
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USES OF ARTOCARPUS HETEROPHYLLUS43: 
The plant is reported to possess antibacterial, anti-inflammatory, antidiabetic, 
antioxidant and immune-modulatory properties. Artocarpus heterophyllus is an 
important source of compounds like morin, dihydromorin, cynomacurin, artocarpin, 
isoartocarpin, cyloartocarpin, artocarpesin, oxydihydroartocarpesin, artocarpetin, 
norartocarpetin, cycloartinone, betulinic acid, artocarpanone and heterophylol which 
are useful in fever, boils, wounds, skin diseases, convulsions, diuretic, constipation, 
ophthalmic disorders and snake bite etc. 
It is richly used in folk practices, root is a remedy for skin diseases and 
asthma and the extract is taken in cases of fever and diarrhoea. The ashes of the 
leaves, burned together with corn and coconut shells are used alone or mixed with 
coconut oil to heal ulcers. Mixed with vinegar, the latex promotes healing of 
abscesses, snakebite and glandular swellings. Heated leaves alone are placed on 
wounds and the bark is made into poultices. The seed starch is given to relieve 
biliousness and the roasted seeds are regarded as aphrodisiac. In Chinese medicine 
the pulp and seeds are considered tonic and nutritious. 
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1. AIM AND OBJECTIVE 
 
AIM  
To successfully evaluate the antihyperlipidaemic and antioxidant activity of 
Artocarpus heterophyllus stem extract on High fat diet-induced hypercholesterolemia 
and triton induced hyperlipidaemia models. 
OBJECTIVE 
1. To conduct a literature survey for establishing the relavence of the study. 
2. To Collection and authenticate of Artocarpus heterophyllus stem. 
3. To successfully extract the dried stem of Artocarpus heterophyllus using 
suitable solvents. 
4. To evaluate toxicological profile of the extract.  
5. To characterize the anti-hyperlipidemic effect as well as antioxidant property 
of the extract.  
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5. MATERIALS AND METHODS 
PLANT MATERIAL 
The fresh bark of Artocarpus Heterophyllus used for the present studies were 
collected from valanchery, kerala in Aug 2016. It was authenticated by Mr.Prabhu 
kumar, Scientist, aryavaidyasala, kotakkal, kerala 
ANIMALS 
Wistar rats (150 – 250 g)  used for the study were obtained from the animal 
house of the Department of Pharmacology,Pathmavathy college of pharmacy, 
Dharmapuri, Tamil Nadu, India. The animals are randomly selected, marked to 
permit individual identification, and kept in their cages for at least 5 days prior to 
dosing to allow for acclimatisation to the laboratory conditions.  The animals were 
housed three per cage in a polypropylene cage and maintained in standard 
laboratory conditions with free access to food and water ad libitum20. All animal  
experiments were conducted in compliance with (Organization for Economic 
Cooperation and Development) OECD Guideline and approved by the Institutional 
Animal Ethics Committee (SCP/CPCSEA/P11/F150/2016) 
CHEMICALS, DRUGS AND INSTRUMENTS 
  All the major chemicals used in the study like Nitro blue tetrazolium (NBT), 
Riboflavin, EDTA, Phosphate buffer, DPPH, Triton, are of analytical grade and are 
procured from imperial chemicals, Coimbatore. 
COLLECTION AND AUTHENTICATION OF PLANT 
 . The fresh bark of Artocarpus Heterophyllus used for the present studies 
were collected from valanchery 
              The dried bark powder of Artocarpusheterophylluswas supplied and 
authenticated by Mr.Prabhu kumar, Scientist, aryavaidyasala, kotakkal, kerala 
 The weighed coarse powder was used for the extraction by successive 
solvent extraction by Soxhlet apparatus using various solvents. 
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EXTRACTION PROCEDURE44 
Preparation of Alcoholic Extract of ArtocarpusHeterophyllusbark 
   The bark were initially collected from the plant and rinsed with distilled water 
and shade dried and then homogenized into fine powder and stored in air tight 
bottles. A total of 10 g of air dried powder was weighed and was placed in 100 mL of 
organic solvents (methanol and ethanol) in a conical flask and then kept in a rotary 
shaker at 190-220 rpm for 24 h. And then it was filtered with the help of muslin cloth 
and centrifuged at 10 000 rpm for 5 min. The supernatant was collected and the 
solvent was evaporated by solvent distillation apparatus to make the final volume of 
one-fourth of the original volume, giving a concentration of 40 mg/mL. It was stored 
at 40 °C in air tight bottles for further studies. 
PHYTOCHEMICAL ANALYSIS45 
Phytochemicals are biologically active, naturally occurring chemical 
compounds found in plants, which provide health benefits for humans further than 
those attributed to macronutrients and micronutrients. Phyto constituents are the 
contributors of pharmacological activities of a plant. The dried powdered sample is 
subjected to qualitative tests for identification of various plant constituents.  
Test for Carbohydrates 
Molisch Test: To the aqueous extract, 1ml of - napthol solution was added and 
Conc. Sulphuric acid was added along the sides of the test tube. Purple or reddish 
violet colour at the junction between the two liquids indicates the presence of 
carbohydrates. 
Fehling Test: To the aqueous extract, equal quantities of Fehling A&B were added 
.Upon heating gently, a brick red precipitate indicates the presence of carbohydrates. 
Benedict’s test: To 5ml of Benedict reagent, 8 drops of solution under test was 
added to the aqueous extract and mixed well. Then it was boiled vigorously for 2 
minutes and cooled. Red precipitate indicates the presence of carbohydrates. 
Test for Proteins 
Biuret Test: To the aqueous extract, 1ml of 40%NaOH and 2drops of 1% copper 
sulphate solution was added. A violet colour indicates the presence of proteins. 
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Xanthophoretic Test: To the aqueous extract, 1ml of conc. Nitric acid was added. 
When a white precipitate was formed, it is boiled and cooled. Then 20% of NaOH or 
ammonia was added. Orange colour indicates the presence of aromatic acids. 
Lead acetate Test: To the aqueous extract, 1ml of lead acetate solution was added. 
A white precipitate indicates the presence of proteins 
Test for Amino acids 
Ninhydrin Test: 2drops of freshly prepared 0.2% ninhydrin reagent was added to 
the aqueous extract and heated. Development of blue colour indicates the presence 
of proteins, peptides or amino acids. 
Test for Fats and Oils  
Place a thick section of drug on glass slide. Add a drop of Sudan Red III reagent. 
After two minutes., wash with 50 % alcohol. Mount in glycerin. Observe under 
microscope. Red globules in the section when viewed under the microscope shows 
the presence of fats or oils. 
Test for Steroids 
Liebermann Burchard Test: The aqueous extract was dissolved in 2ml chloroform 
in dry test tube. 10 drops of acetic anhydride and 2 drops of conc. sulphuric acid 
were added. The solution becomes red and then blue and finally bluish green in 
colour indicates the presence of steroids. 
Salkowaski Test: The aqueous extract was dissolved in chloroform and equal 
volume of sulphuric acid was added to it. Bluish red to cherry red colour was 
observed in chloroform layer, whereas acid layer assumes marked green 
fluorescence indicates the presence of steroids. 
Test for Cardiac glycosides 
Keller-killiani Test: Test sample was dissolved in acetic acid containing traces of 
ferric chloride and transferred to the surface of conc. Sulphuric acid. At the junction, 
reddish brown colour was formed, which gradually becomes blue indicates the 
presence of cardiac glycosides. 
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Test for Saponins 
Foam Test: About 1ml of aqueous extract is diluted separately with distilled water to 
20ml and shaken in a graduated cylinder for 15 minutes. A1cm layer of foam 
indicates the presence of saponins. 
Test for Flavonoids 
Sulphuric Acid Test: On addition of sulphuric acid (66% or 80%) flavons and 
flavonols dissolves into it and give a deep yellow solution. 
Heat the test solution with Zinc and HCl, pink to red colur observation shows the 
presence of flavonoids. 
Test for Alkaloids 
Dragendroff’s Test: To the  aqueous extract, add 1ml of Dragendroff’s reagent. An 
orange red coloured precipitate indicates the presence of alkaloids. 
Wagner’s Test: To the aqueous extract, add 1ml of Wagner’s reagent. Reddish 
brown coloured precipitate indicates the presence of alkaloids. 
Mayer’s Test: To the aqueous extract, add 1ml of Mayer’s reagent. A dull white 
coloured precipitate indicates the presence of alkaloids. 
Test for Phenolic compounds and Tannins 
Small quantities of alcoholic and aqueous extracts in water were tested for the 
presence of phenolic compounds and tannins with dilute ferric chloride solution (5%), 
1% solution of gelatin containing 10% sodium chloride, 10% lead acetate and 
bromine solutions. The respective observations may be deep blue black colour, 
white precipitate, white precipitate, decolouration of bromine water showing the 
presence of tannins and phenolic compounds. 
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IN VITRO ANTIOXIDANT ACTIVITIES 
 
A. SUPEROXIDE  RADICAL SCAVENGING ACTIVITY 46 
Principle: 
The superoxide anion radical scavenging activity was determined by nitro blue 
tetrazolium (NBT) reduction method of Mc Cord and Fridovich (1969). The assay is 
based on the ability of drug to inhibit the reduction of nitro blue tetrazolium (NBT) by 
Superoxide, which is generated by the reaction of photo reduction of riboflavin within 
the system. The superoxide radical thus generated reduce the NBT to a blue colored 
complex. 
Reagents: 
 Nitro blue tetrazolium (NBT)   -  1.5nm  (12.3mg/10ml) 
 Riboflavin                     -   0.12µm  (4.5mg/100ml) 
 NaCN/EDTA         -   0.0015% NaCN in 0.1M EDTA 
 Phosphate buffer         -   0.06M  ( pH 7.8 ) 
Procedure: 
The reaction mixture contained EDTA (0.1 M), 0.3mM NaCN, Riboflavin 
(0.12mM), NBT (1.5 n moles), Phosphate buffer (67mM, pH 7.8) and various 
concentrations of the bark extract in a final volume of 3ml. The tubes were 
illuminated under incandescent lamp for 15min. The optical density at 560 nm was 
measured before and after illumination. The inhibition of superoxide radical 
generation was determined by comparing the absorbance values of the control with 
that of bark extract and extract. Vitamin C was used as positive control. The 
concentration of extract required to scavenge 50% superoxide anion (IC50 value) was 
then calculated.   
Calculation:  
    % inhibition   =        × 100 
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B. DPPH RADICAL REDUCING ACTIVITY47: 
Principle: 
It is a rapid and simple method to measure antioxidant capacity. It involves 
the use of free radical, DPPH (2, 2- Diphenyl - 1- picrylhydrazyl) (Aquino et al, 2001). 
The odd electron in the DPPH free radical gives a strong absorption maximum at 
517nm and is purple in color. The color turns from purple to yellow when the odd 
electron of DPPH radical becomes paired with hydrogen from a free radical 
scavenging antioxidant to form the reduced DPPH-H. The resulting decolourisation is 
stoichiometric with respect to the number of electrons captured. 
Reagents: 
 DPPH  -   3mg in 25ml methanol (stored in dark bottle) 
 Methanol        
Procedure: 
Freshly prepared DPPH (187 µl) was taken in different test tubes protected 
from sunlight. To this solution added different concentrations (0, 25, 50, 
75,100,150,200µg/ml) of bark extract and fraction-IV. The volume was made up to 
1ml with methanol. Keep the tubes in dark and after 20 min absorbance was 
measured at 515nm. Methanol was used as blank and vitamin C was used as 
positive control. The concentration of test materials to scavenge 50% DPPH radical 
(IC50 value) was calculated from the graph plotted with % inhibition against 
concentration. 
Calculation:  
   % inhibition   =       × 100 
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PHARMACOLOGICAL SCREENING 
ACUTE TOXICITY STUDY 48,49,50 
Experimental Protocol: 
Guideline                      :  OECD-423 
CPCSEA Ref. No               :  SCP/CPCSEA/P11/F150/2016 
Test                                  :  Limit test 
Species                              :  Rattusnorvegicus 
Strain                                 : Albino Wistar rats 
Number of animals         :  24 animals (6 for each group) 
Sex                                    :  Female 
Initial dose                     :  5mg/kg 
Route of administration :  Oral 
Duration                         :  3hr close observation, followed by 14 days  
  observation 
Others                             :  Body weight, mortality status 
Parameters                    :  CNS, ANS and behavioural changes 
Blood collection            :  Not needed 
Sacrifice                         :  Not needed 
Selection of Test animal 
 Female adult Wistar rats of 8-12 weeks are selected. Nulliparous and non-pregnant 
animals were obtained from the centralized animal house of Pathmavathi College of 
Pharmacy, Dharmapuri. and they are acclimatized for holding 1 week prior to dosing. 
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Housing and feeding conditions for Experimental Animals 
Temperature - As per OECD guideline-420 the temperature of animal house were 
maintained at 220C±30C. 
Humidity - The relative humidity of animal room maintained at 50-60% preferably 
not exceeds 70% (OECD guidelines-420, 2001). Otherwise there may be chances of 
developing lesions such as ring tail and food consumption may be increased. 
Light – The sequence of light used was 12 hrs light and 12 hrs dark. 
Caging – Polypropylene cages with solid bottom and walls. The lids are made up of 
stainless steel grill which is capable to hold both feed and water.  
Feeding condition and feed – Sterile laboratory feed (ad libitum) and water daily. 
The feed used were brown coloured chow diet. 
Drug administration  
Animals are fasted prior to dosing (food but not water should be withheld for 
overnight).After that animals are weighed and the test substance administered. The 
healthy rats has been taken and divided into 4 different groups. The test substance 
is administered in a single dose by oral gavages, using a curved and ball tipped 
stainless steel feeding needle. 
Experimental Design 
In this study, 4 groups of 6 rats each were given 5, 50 and 300 and 2000 mg/kg of 
the decoction (p.o.).  After drug administration the food is withheld for 3 hours. The 
animals are observed continuously for the first 2 hours, then occasionally up to 6 
hours and then daily up to 14 days, post treatment to observe for any symptoms of 
toxicity and mortality. Daily observations on the changes in skin and fur, eyes and 
mucus membrane (nasal), autonomic effects (salivation, lacrimation, gauntness and  
piloerection) and central nervous system (gait, tremors and convulsion) were carried 
out and changes were noted (OECD, 2001). 
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Table 4 – acute Toxicity study Design 
 
 
 
 
 
 
Clinical observation51 
All animals were monitored continuously with special attention for 4 hrs after dosing 
for signs of toxicity. Additional observations are also done for the next 14 days for 
any other behavioural or clinical signs of toxicity. Weight changes are calculated. At 
the end of the test animals are weighed. LD50 values are established using the 
formula. 
Dose Calculation Equation 
LD50 = higher dose ─ Σ (a x b)/n 
           Where, 
a = dose difference 
b = animal died 
n = No. of animals in each group 
    ED50  =LD50 
     10 
 
 
 
 
GROUP Number of 
Animals 
DOSE 
(mg/kg) 
Group 1 6 5 
Group 2 6 50 
Group 3 6 300 
Group 4 6 2000 
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ANTIHYPERLIPEDEMIC ACTIVITY 
HIGH – CHOLESTEROL DIET MODEL 
High fat diet induced hyperlipidemic model Preparation of feed 
 
Method of Blank et el52 with modification was used to produce high fat diet 
induced hyperlipidemia.Normal animal food pellets were crushed in mortar and 
pestle to crush into small pieces and then grinded into fine powder in mixer grinder. 
The other ingredients i.e. cholesterol l 2% , Cholic acid 1% , sucrose 40% , and 
coconut oil 10% were added in the mixer grinder in an ascending order of their 
quantity and mixed well. This dried powder was then mixed with same quantity of 
water every time to make small balls of feed and later this was stored in self-
sealing plastic covers in refrigerator at 2°C to 8°C. The feed for normal group was 
prepared similarly by grinding only the normal food pellets and then mixing with 
water without the other excipients.5,54 This preparation of feed was done once in 
three days for all the animals. The animals were administered with the high fat diet 
for 30 days. Check the serum blood cholesterol levels 
Study design 
Wistar rats weighing 150-180 gm, were divided into 5 groups of 6 animals 
each. 
 
Group I- served +as normal control and were given only vehicle (distilled water) 
 
Group II- received high fat diet served as hyperlipedemic control 
 
Group III - received atorvastatin 10mg/kg served as standard drug  
 
Group IV- received 200mg/kg AAHP  
 
Group V- received 400mg/kg of AAHP 
 
TRITON INDUCED HYPERLIPIDEMIC RATS55,56 
30 Wistar rats were randomly divided into 5 groups of 6 each. The first group 
was given standard pellet diet, water and orally administered with 5% CMC. The 
II,III,IV,Vgroup animals were injected i.p. with 10% aqueous solution of Triton 
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100mg /kg body weight. After 72 hours of triton injection, the second group 
received a daily dose of 5% CMC (p.o) for 7 days. The thirdgroup was 
administered with the standard Atorvastatin 10mg/kg, p.o. for 7 days, fourth and 
fifth group was administered a daily dose of  AAHP 200 and 400 mg/kg suspended 
in 5%CMC,p.o., for 7 days, after inducing hyperlipidemia.. Food was withdrawn 10h 
prior to the blood sampling. The control group animals received the vehicle in the 
same volume orally. 
Group 1: Administered vehicle and served as normal control. 
Group 2: Administered Triton X 100 (TR) and served as hyperlipidaemia 
control.  
Group 3: Administered Standard Atorvastatin (10mg/kg), p.o 
Group 4: Administered AAHB (200mg/kg), p.o. 
Group 5: Administered AAHB (400mg/kg), p.o. 
 
BIOCHEMICAL ANALYSIS OF SERUM 
Serum samples were analysed for total cholesterol, High density lipoproteins, Low 
density lipoproteins and very low density lipoproteins using standard enzymatic 
assay kit. 
Estimation of lipids: 
A. Total cholesterol: Cholesterol in serum was estimated by using an Ecoline 
Diagnostic Kit. Cholesterol and its esters were released from lipoprotein by 
detergents. Cholesterol esterase hydrolyzes the esters. In the subsequent enzymatic 
oxidation by cholesterol oxidase, H2O2 was formed. This was converted into a 
coloredquinineimine in a reaction with 4-aminoantipyine and phenol catalyzed by 
peroxidase. The absorbance of the sample and of the standard was measured 
against the reagent blank value at 546nm. Cholesterol level in serum was expressed 
as mg/dL. 
B.Triglycerides: Triglycerides level in serum was estimated using Ecoline 
Diagnostic Kit.  
                                        Lipase 
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        Triglycerides                                 Glycerol + Fatty acid  
                                      GK 
       Triglycerides                                  Glycerol + Fatty acid 
                                                     GPO    
      Glycerol-3-phosphate + O2  Dihydroxy-acetone-Phosphate + H2O2 
 
      2H2O2 + Aminoantipyrine + 4 chlorophenol  Chinonimine + 4H2O 
     The absorbance of the sample and of the standard was measured against 
the reagent blank value at 56nm. Triglyceride level in serum was expressed as 
mg/dL.  
C. HDL cholesterol: The cholesterol was separated from serum after precipitation of 
LDL cholesterol by phosphotungstic acid precipitating reagent. The supernatant after 
centrifugation was estimated using Ecoline Diagnostic Kits. The absorbance of the 
sample and of the standard was measured against the reagent blank value at 
546nm. HDL cholesterol level in serum expressed as mg/dL. 
D. LDL cholesterol:    LDL cholesterol was calculated by using the formula 
          LDL cholesterol = Total cholesterol – [HDL cholesterol – Triglycerides/5]. 
         LDL cholesterol level in plasma was expressed as mg/dL. 
E. VLDL cholesterol:  VLDL cholesterol was calculated by using the formula 
        VLDL cholesterol = Total cholesterol – HDL cholesterol – Triglycerides- LDL. 
 
STASTICAL ANALYSIS57-59 
Data were statically analysed as mean + SEM and expressed as just 
significant P<0.05 and significant P<0.01 as the case may be using one way ANOVA 
followed by Dunnett’s multiple comparison test.  
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6. RESULTS 
EXTRACTION OF ARTOCARPUS HETEROPHYLLUS BARK  
The percentage yield of the Artocarpus Heterophyllus bark was found to be 
1.03%w/v. 
Table 5 - Extraction of ArtocarpusHeterophyllus Bark  
Preliminary phyto chemical screening 
 Alcoholic Extract of Artocarpus Heterophyllus bark(AAHB) was subjected 
various chemical tested as per the standard methods for the identification of the 
various constituents. The result if this phyto chemical analysis is listed below. 
Table 6 - Qualitative phyto chemical screening of AAHB 
PLANT CONSTITUENT 
INFERENCE 
Ethanol Extract 
Carbohydrate - 
Alkaloids + 
Flavonoids + 
Proteins and amino 
acids 
+ 
Glycosides - 
Fixed oil + 
Terpenoids + 
Volatile oil - 
Tannins - 
“+” Presence,“-” Absence. 
Plant 
Part 
used 
Method of 
Extraction 
Solvents 
Percentage 
Yield (%W/V) 
ArtocarpusHeterophyllus Bark Maceration 
Ethanol 
(95%) 
1.03 
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II-IN VITROANTIOXIDANT ACTIVITIES:    
A. EFFECT OF SUPEROXIDE RADICAL SCAVENGING ACTIVITY:  
Superoxide generated in the photo reduction of riboflavin was effectively inhibited by 
the addition of varying concentrations (0-14L/ml) of extract table 3. The concentration of 
the AAHBneeded to scavenge 50% superoxide anion (IC50) was found to be 13 g/ml 
(figure 1) Vitamin C which was used as a positive control had an IC50 value of 4.5 g/ml. 
Table 7 - Effect of AAHB on Superoxide in vitroRadical Scavenging Activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are mean ± SD of three individual experiments 
AAHB - Alcoholic Extract ofArtocarpus Heterophyllus bark 
 
 
Concentratio
n 
(µg/ml) 
Absorbance 
Percentage 
inhibition 
AAHB Vitamin C AAHB 
Vitamin 
C 
0 0.78 0.78 0 0 
2 0.72 0.54 7.6 30.76 
4 0.65 0.41 16.6 47.43 
6 0.58 0.36 25.64 53.84 
8 0.54 0.25 30.76 67.94 
10 0.47 0.19 39.47 75.64 
12 0.41 0.14 47.43 82.05 
14 0.35 0.11 55.12 85.89 
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Figure 5: Effect of AAHB on Superoxide in vitroRadical Scavenging Activity 
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B. EFFECT OF AAHB ON DPPH RADICAL REDUCING ACTIVITY : 
The DPPH radical was effectively scavenged by AAHB. A dose dependent 
reduction of was observed within the range of concentrations (0-100g/ml) of Vitamin 
C which was used as the positive control exhibited an IC50 value of 21.6 g/ml. 
Table 8 - Study of in vitro DPPH Radical Scavenging Activity 
AAHB - Alcoholic Extract of Artocarpus Heterophyllus bark 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration 
(µL/ml) 
Absorbance Percentage inhibition 
AAHB VitaminC AAHB VitaminC 
1 0.694 0.58 0.5 15.8 
10 0.676 0.487 4.35 29.9 
20 0.640 0.361 9.03 49 
30 0.60 0.121 14.2 67.8 
40 0.566 0.101 19.2 87.3 
50 0.530 0.046 23.4 97.3 
60 0.461 0.06 29.2 96.1 
70 0.459 0.05 36.3 96.2 
80 0.40 0.05 41.9 96.2 
90 0.36 0.04 48.13 97.5 
1OO 0.327 0.03 54.23 98.3 
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Figure 6 -DPPH radical reducing activity of AAHB and vitamin C. 
 
 
Acute Toxicity Study 
There was no mortality or signs of toxicity up to the limit dose of 2000  mg/kg 
in treated rats. All 24 rats were normal throughout the study and survived until the 
end of the 14-day experiment period. Animal wellness parameters were observed 
continuously for the first 2 hours, then occasionally up to 6 hours and then daily up to 
14 days as per paragraph 24 and 25 of OECD Guideline 423. Experimental 
observations are recorded systematically for each group. The parameters 
considered are changes in skin and fur, eyes and mucous membrane and also 
respiratory and circulatory, autonomic and central nervous system, somatomotor 
activity and behavioral pattern. Special attention is given for the observations of 
tremor, convulsion, salivation, diarrhea, lethargy, sleep and coma. 
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Table9 - Changes in wellness parameters observed 
forArtocarpusHeterophyllus Bark Extract treatedwistar rats. 
Sl 
no 
Response 
Group1(5mg/k
g) 
Group 2 
(50mg/kg) 
Group 3 
(300mg/kg) 
Group 4 
(2000mg/kg) 
Before After 
Befo
re 
After 
Befo
re 
After 
Befo
re 
After 
1 Alertness Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
2 Grooming Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
3 Anxiety Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
4 Roaming Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
5 Tremor Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
6 Convulsion Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
7 Depression Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
8 
Gripping 
strength 
Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
9 Scratching 
Presen
t 
Prese
nt 
Pres
ent 
Pres
ent 
Pres
ent 
Pres
ent 
Pres
ent 
Prese
nt 
10 Defecation Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
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11 Writhing Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
12 Pupils Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
13 Urination Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
14 Salivation Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
15 Skin and fur Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
16 Lacrimation Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
17 Pilo erection Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
18 Nail status Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
19 Gauntness Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
21 Diarrhoea Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
22 Sleep Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
23 Coma Absent 
Absen
t 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
Abse
nt 
24 Lethargy Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
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25 
Mucous 
membrane 
Normal 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
Norm
al 
 
Effect of AAHP on lipid profile in high fat diet induced model 
 
In high fat diet induce model, oral administration of AAHP (200 mg/kg and 
400mg/kg, p.o.) significantly reduced the serum totalcholesterol (TC), triglyceride 
(TG), low density lipoprotein-cholesterol (LDL-C), VLDL-cholesterol levels but 
significantly increased serum HDL-cholesterol level as compared with positive 
control group. This study shows serum lipid parameters in animals were significantly 
reduced (p<0.001,) by fourteen days treatment with AAHP at dose levels 200 mg/kg 
and 400 mg/kg, when compared with control group. 400 mg/kg of AAHP group 
animals has shown very significant (p<0.001) compared with control group 
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ANTHYPERLIPEDEMIC ACTIVITY 
Table 10 -Effect of AAHB onLipid Profile in high-cholesterol diet induced 
hyperlipidaemia 
GROUP 
Total 
Cholesterol 
(mg/dl) 
HDL (mg/dl) 
Triglycerides 
(mg/dl) 
VLDL mg/dl) LDL (mg/dl) 
Control 82.1±3.79 42.12±1.34 68.89±2.12 12.79±0.42  26.39±3.55 
Positive control 146.72±2.5 34.19±2.82 142.18±3.80 25.83±0.75  64.35±2.82 
Atorvastatin 
10mg/kg 
87.92±1.76 46.34±2.02 99.1±2.35*** 20.53±0.64  21.23±2.42** 
200mg/kg 
AAHP 
108.42±2.35 40.81±2.40 116.02±2.10** 23.5±0.42  44.73±2.33 
400mg/kg 
AAHP 
92.35±1.63** 
43.49±2.18**
* 
101.06±2.89 20.6±0.60  28.59±2.02** 
 
Values were mean ±sd (n=6). Values are statistically significant at *P<0.05 and more 
significant at **P<0.01,***P<0.001 Vshyperlipidemic control using one way ANOVA 
followed by Dunnet’s test. 
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Table 11 – Effect of AAHB on Total Cholesterol in high cholesterol diet induced 
hyperlipidaemia 
GROUP TOTAL CHOLESTEROL (mg/dl) 
Control 82.1±3.79 
Toxic control 146.72±2.5 
Standard 
(Atorvastatin 10mg/kg) 
87.92±1.76 
AAHB(200mg/kg) 108.42±2.35 
AAHB(400mg/kg) 92.35±1.63** 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
Figure 7- Effect of AAHB on Total Cholesterol in high cholesterol diet induced 
hyperlipidaemia 
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Table 12- Effect of AAHB on HDL in high cholesterol diet induced 
hyperlipidaemia 
GROUP HDL (mg/dl) 
Control 42.12±1.34 
Toxic control 34.19±2.82 
Standard 
(Atorvastatin 10mg/kg) 
46.34±2.02 
AAHB(200mg/kg) 40.81±2.40 
AAHB(400mg/kg) 43.49±2.18*** 
 
AAHB - Alcoholic Extract ofArtocarpus Heterophyllus bark 
Figure 8 - Effect of AAHB on HDL in high cholesterol diet induced 
hyperlipidaemia 
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Table13 - Effect of AAHB on Triglycerides in high cholesterol diet induced 
hyperlipidaemia 
GROUP TRIGLYCERIDES (mg/dl) 
Control 68.89±2.12 
Toxic control 142.18±3.80 
Standard 
(Atorvastatin 10mg/kg) 
99.1±2.35*** 
AAHB(200mg/kg) 116.02±2.10** 
AAHB(400mg/kg) 101.06±2.89 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
Figure 9 - Effect of AAHB on Triglycerides in high cholesterol diet induced 
hyperlipidaemia 
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Table14 - Effect of AAHB on LDL in high cholesterol diet induced 
hyperlipidaemia 
GROUP LDL (mg/dl) 
Control 26.39±3.55 
Toxic control 64.35±2.82 
Standard 
(Atorvastatin 10mg/kg) 
21.23±2.42** 
AAHB(200mg/kg) 44.73±2.33 
AAHB(400mg/kg) 28.59±2.02** 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
Figure10 - Effect of AAHB on LDLin high cholesterol diet induced 
hyperlipidaemia 
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Table15 - Effect of AAHB on VLDL in high cholesterol diet induced 
hyperlipidaemia 
 
GROUP VLDL (mg/dl) 
Control 12.79±0.42 
Toxic control 25.83±0.75 
Standard 
(Atorvastatin 10mg/kg) 
20.53±0.64 
AAHB(200mg/kg) 23.5±0.42 
AAHB(400mg/kg) 20.6±0.60 
 
 
AAHB - Alcoholic Extract of Artocarpus Heterophyllus bark 
Figure11 -Effect of AAHB on VLDL in high cholesterol diet induced 
hyperlipidaemia 
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Effect of Alcoholic Extract ofArtocarpusHeterophyllusbark on lipid profile in 
Triton inducedhyperlipidemia 
In triton induced study results shows serum lipid paremeters in animals 
were significantly reduced (p<0.01,) by seven days treatment with  AAHP at dose 
levels 200 mg/kg and 400 mg/kg, when compared with control group 400 mg/kg of 
AAHP group animals has shown significant (p<0.001) compared with control group. 
At this time, an increased level of HDL was also observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  RESULTS 
 
DEPARTMENT OF PHARMACOLOGY, PADMAVATHI COLLEGE OF PHARMACY, DHARMAPURI Page 57 
 
TRITON INDUCED HYPERLIPIDEMIA MODEL 
Table 16 -EFFECT OF AAHBON LIPID PROFILE TRITON INDUCED 
HYPERLIPIDEMIA 
GROUP 
Total 
Cholesterol  
(mg/dl) 
HDL (mg/dl) 
Triglycerides 
(mg/dl) 
VLDL 
(mg/dl) 
LDL 
(mg/dl) 
Control 82.63±0.20 42.70±0.69 67.23±0.78 14.04±0.50 26.09±0.95 
Positive 
control 
145.16±2.25 31.04±2.33 127.56±2.54 27.31±0.99 66.99±1.93 
Standard 
(Atorvastatin 
10mg/kg) 
86.40±0.91*** 45.40±0.70 76.07±0.53 18.75±0.34** 22.74±0.59 
AAHP 
(200mg/kg) 
108.56±0.94 39.12±0.52 96.15±0.62* 23.88±0.5 38.35±0.61 
AAHP 
(400mg/kg) 
91.36±1.72*** 42.79±0.91** 82.18±0.86 20.5±0.94 
25.09±0.73*
* 
 
Values were mean ±sd (n=6). Values are statistically significant at 
*P<0.05 and more significant at **P<0.01,***P<0.001 Vshyperlipidemic 
control using one way ANOVA followed by Dunnet’s test 
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Table 17 – Effect of AAHB on Total Cholesterol in Triton induced 
Hyperlipidaemia  
 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
 
Figure: 12 - Effect of AAHB on Total Cholesterol in Triton induced 
Hyperlipidaemia  
 
 
GROUP TOTAL CHOLESTEROL (mg/dl) 
Control 82.63±0.20 
Toxic control 145.16±2.25 
Standard 
(Atorvastatin 10mg/kg) 
86.40±0.91*** 
AAHB (200mg/kg) 108.56±0.94 
AAHB (400mg/kg) 91.36±1.72*** 
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Table 18 - Effect of AAHB on HDL in Triton induced Hyperlipidaemia  
 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
 
Figure 13 - Effect of AAHB on Total Cholesterol in Triton induced 
Hyperlipidaemia  
 
GROUP HDL (mg/dl) 
Control 42.70±0.69 
Toxic control 31.04±2.33 
Standard 
(Atorvastatin 10mg/kg) 
45.40±0.70 
AAHP (200mg/kg) 39.12±0.52 
AAHP (400mg/kg) 42.79±0.91** 
  RESULTS 
 
DEPARTMENT OF PHARMACOLOGY, PADMAVATHI COLLEGE OF PHARMACY, DHARMAPURI Page 60 
 
Table19 - Effect of AAHB on Triglycerides in Triton induced Hyperlipidaemia  
GROUP TRIGLYCERIDES (mg/dl) 
Control 67.23±0.78 
Toxic control 127.56±2.54 
Standard 
(Atorvastatin 10mg/kg) 
76.07±0.53 
AAHB(200mg/kg) 96.15±0.62* 
AAHB(400mg/kg) 82.18±0.86 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
 
 
 
Figure14 - Effect of AAHB on Triglycerides in Triton induced Hyperlipidaemia  
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Table 20 - Effect of AAHB on LDL in Triton induced Hyperlipidaemia  
 
GROUP LDL (mg/dl) 
Control 26.09±0.95 
Toxic control 66.99±1.93 
Standard 
(Atorvastatin 10mg/kg) 
22.74±0.59 
AAHP (200mg/kg) 38.35±0.61 
AAHP (400mg/kg) 25.09±0.73** 
 
AAHB - Alcoholic Extract of Artocarpus Heterophyllus bark 
Figure 15 - Effect of AAHB on Total Cholesterol in Triton induced 
Hyperlipidaemia  
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Table 21 - Effect of AAHB on VLDL in Triton induced Hyperlipidaemia  
 
GROUP VLDL (mg/dl) 
Control 14.04±0.50 
Toxic control 27.31±0.99 
Standard 
(Atorvastatin 10mg/kg) 
18.75±0.34** 
AAHP (200mg/kg) 23.88±0.5 
AAHP (400mg/kg) 20.5±0.94 
 
AAHB - Alcoholic Extract ofArtocarpusHeterophyllusbark 
Figure 16 - Effect of AAHB on VLDL in Triton induced Hyperlipidaemia  
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7. DISCUSSION 
Artocarpus heterophyllus is a large, evergreen tree found generally in 
Western Ghats of India, Malaysia and also found in central and eastern Africa, 
south-eastern Asia, the Caribbean, Florida, Brazil, Australia, Puerto Rico and many 
Pacific Islands. Different parts of the plant, studied revealed antibacterial, anti-
inflammatory, antidiabetic, antioxidant and immune modulatory properties.   
The antioxidant screening shows that that it showed reducing power to DPPH 
radicals. But the efficiency showed is far below from Vitamin C. Considering super 
oxide radical scavenging studies, ethanolic extract shows similar percentage of 
inhibition comparing the standard drug.  
Accute phase toxicological studies reports no mortality or signs of toxicity up 
to the limit dose of 2000  mg/kg in treated rats. All 24 rats were normal throughout 
the study and survived until the end of the 14-day experiment period.  
The preliminary phytochemical screening of plant bark extracts indicate in 
presence of flavonoid, alkaloid, tannins, terpenoids and glycosides may accounts 
antioxidant and anti-hyprelipidaemic potential. 
The presences of various phyto-constituents like alkaloids, flavonoids, 
terpenoids, phytosterols, saponinsetc, were responsible for the specified 
pharmacological effects. Alcoholic extracts shows more number of 
phytoconstituents.. 
Oral administration of ethanolic bark extracts significantly reduced the 
cholesterol, triglycerides, low density lipoproteins, very low density lipoproteins and 
significantly increased the HDL – cholesterol level as compared with high cholesterol 
diet induced hyperlipidemic animals.  The results were significant with the p value 
(p<0.001). 
Triton WR 1339 is the non-ionic detergent, induces acute hyperlipidemiaby 
raising cholesterol levels raise 2-3 times within 24 hours of administration.. The 
mechanism of the Triton induced hypercholesterolemia is thought to be due to 
increased hepatic synthesis of cholesterol through the ability of Triton to interfere 
with the uptake of plasma lipids by the tissue.  
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In triton induced study results shows serum lipid paremeters in animals were 
significantly reduced (p<0.01,) by seven days treatment with  AAHP at dose levels 
200 mg/kg and 400 mg/kg, when compared with control group 400 mg/kg of AAHP 
group animals has shown significant (p<0.001) compared with control group. At 
this time, an increased level of HDL was also observed. 
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8. CONCLUSION 
The preliminary phytochemical screening revealed the presence of sterols, 
flavonoids, polyphenolics and fixed oil in ethanolic extract and sterols, proteins, 
polyphenolics, pectin’s in the aqueous extract. 
The results indicates that the extract possess anti-oxidant properties, but 
when compared with a standard marketed drug, in superoxide radical scavenging 
activity studies the  percentage inhibition shown by the extract was far less 
comparing standard drug and in DPPH radical reducing studies we observed a 
similar percentage inhibition to that of standard drug. 
Ethanolic extract showed decreased blood lipids in hyperlipidemic rats when 
compared to normal and standard groups The bark extracts shows a decreased in 
the  TC, TG, and LDL and an increase in HDL in biphasic model of the Triton 
induced hyperlipidaemia rats, Diet induced hyperlipidemic rats and also in 
Normocholesteremic rats.  
The present study concludes that the extracts of Artocarpusheterophyllus bark 
possess significant anti-oxidant and anti-hyperlipidemic activity. 
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